Porphyrins and Their Derivatives in Cancer Therapy: Current Advances, Mechanistic Insights, and Prospective Directions
Molecular Pharmaceutics · 02.06.2025 · 22 (6) · 2765-2782
DOI: 10.1021/acs.molpharmaceut.4c01359 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 28.04.2025. Verfasst von Min Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, China. Hauptthemen laut MEDLINE: Porphyrins, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: Nantong University, National Natural Science Foundation of China, College Students? Innovation and Entrepreneurship Training Program of Nantong University.
Abstract (Originalsprache)
Porphyrin and its derivatives are widely used in cancer therapy due to their strong photon absorption capabilities and moderate light stability. Due to their hydrophobic nature, porphyrins with tetrapyrrolic macrocycles ease self-aggregation in physiological conditions. Instead, exploiting the C4 symmetry structure for self-assembly is beneficial to improve the bioavailability of porphyrin and its derivatives. Herein, this Review outlines porphyrin-based nanoformulations for therapeutic applications in cancer treatment. The typical pharmaceutical application of the integrated porphyrinic structure is systematically summarized, focusing on the typical synthetic methodologies and structure-functionality relationship. Additionally, therapeutic modalities (e.g., photothermal, photodynamic, and sonodynamic) and their synergy mechanism in regulated cell death are overviewed. Special attention is given to emerging technologies in nanocatalytic therapy, therapeutic vaccines, and proteolysis-targeting chimeras, which align with the trend toward personalization and minimal invasiveness in healthcare. Finally, we discuss the challenges and limitations of porphyrinic nanoformulations and explore their future directions in the healthcare sector, aiming to bridge the gap between research and practical clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Nantong University, Nantong, Jiangsu 226001, China.
ORCID-Profile: Weiqi Wang
Förderung
- Nantong University
- National Natural Science Foundation of China
- College Students? Innovation and Entrepreneurship Training Program of Nantong University
- Undergraduate Innovation and Entrepreneurship Training Program of Jiangsu Province
- Jiangsu Provincial Association for Science and Technology Youth Science and Technology Talent Support Project
Zitieren
APA
Chen, M., Ji, S., Liu, X., Zheng, X., Zhou, M., & Wang, W. (2025). Porphyrins and Their Derivatives in Cancer Therapy: Current Advances, Mechanistic Insights, and Prospective Directions. Molecular Pharmaceutics, 22(6), 2765-2782. https://doi.org/10.1021/acs.molpharmaceut.4c01359
Vancouver
Chen M, Ji S, Liu X, Zheng X, Zhou M, Wang W. Porphyrins and Their Derivatives in Cancer Therapy: Current Advances, Mechanistic Insights, and Prospective Directions. Molecular Pharmaceutics. 2025;22(6):2765-2782. doi:10.1021/acs.molpharmaceut.4c01359
BibTeX
@article{Chen2025,
author = {Chen, Min and Ji, Shuying and Liu, Xingxing and Zheng, Xiaohua and Zhou, Mengjiao and Wang, Weiqi},
title = {Porphyrins and Their Derivatives in Cancer Therapy: Current Advances, Mechanistic Insights, and Prospective Directions},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {6},
pages = {2765--2782},
doi = {10.1021/acs.molpharmaceut.4c01359}
}
EUVIMED